# To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam)

> **NCT00345956** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 375 (estimated)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** Human rotavirus liquid vaccine

## Key facts

- **NCT ID:** NCT00345956
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 375 (ESTIMATED)
- **Last updated:** 2016-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00345956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00345956, "To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00345956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*